DDInter478 DDInter1625
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296]
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Daratumumab may lead to a major life threatening interaction when taken with Cladribine
Daratumumab may lead to a major life threatening interaction when taken with Rotavirus vaccine